Study identifier:D2890C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A phase I, single-center, single-blind, randomized, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of oral AZD8165 after single oral ascending doses in healthy male subjects
thrombin inhibition
Phase 1
Yes
AZD8165
Male
9
Interventional
18 Years - 45 Years
Allocation: N/A
Endpoint Classification: Pharmacokinetics/dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Other
Verified 01 Sept 2010 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 | Drug: AZD8165 Oral suspension, 2 mg/mL and 20 mg/mL, single doses |